Bisphosphonates and bone metastases: current status and future directions

References

• Rubin P. Current concept in cancer: metastases and disseminated cancer. Int. J. Radiat. Oncol. Biol. Phys. 1, 1199–1200 (1976).
   Web of Science ®Google Scholar
• Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br. J. Cancer 55, 61–66 (1987).
   PubMed Web of Science ®Google Scholar
• Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer: implications for management. Eur. J. Cancer 36, 476–482 (2000).
   PubMed Web of Science ®Google Scholar
• Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials. Cancer 88, 1082–1090 (2000).
   PubMed Web of Science ®Google Scholar
• British Association of Surgical OncologyGuidelines. The management of metastatic bone disease in the United Kingdom. The Breast Specialty Group of the British Association of Surgical Oncology. Eur. J. Surg. Oncol. 25, 3–23 (1999).
   PubMedGoogle Scholar
• Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27, 165–176 (2001).
   PubMed Web of Science ®Google Scholar
• Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. Br. Med. J. 327(7413), 469 (2003).
   PubMed Web of Science ®Google Scholar
• Coleman RE. Bisphosphonates: clinical experience. Oncologist 9, 14–27 (2004).
   PubMed Web of Science ®Google Scholar
• Ross JR, Saunders Y, Edmonds PM et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol. Assess. 8(4), 1–176 (2004).
   PubMed Web of Science ®Google Scholar
• Hillner B, Ingle J, Chelebowski R et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. 94, 4042–4057 (2003).
   Google Scholar
• Turner CH. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int. 13(2), 97–104 (2002).
   PubMed Web of Science ®Google Scholar
• Guise TA, Mundy GR. Cancer and bone. Endocr. Rev. 19, 18–54 (1998).
   PubMed Web of Science ®Google Scholar
• Orr FW, Lee J, Duivenvoorden WC, Singh G. Pathophysiologic interactions in skeletal metastasis. Cancer 88, 2912–2918 (2000).
   PubMedGoogle Scholar
• Kurth AA, Muller R. The effect of an osteolytic tumor on the three-dimensional trabecular bone morphology in an animal model. Skeletal Radiol. 30, 94–98 (2001).
   PubMed Web of Science ®Google Scholar
• Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 88, 2892–2898 (2000).
   PubMedGoogle Scholar
• Roodman GD. Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655–1664 (2004).
   PubMed Web of Science ®Google Scholar
• Guise TA, Chirgwin JM. Role of bisphosphonates in prostate cancer bone metastases. Semin. Oncol. 30, 717–723 (2003).
   PubMed Web of Science ®Google Scholar
• Fleisch H. Bisphosphonates: mechanism of action. Endocr. Rev. 19, 80–100 (1998).
   PubMed Web of Science ®Google Scholar
• Neville-Webbe HL, Holen I, Coleman RE. The antitumour activity of bisphosphonates. Cancer Treat. Rev. 28, 305–319 (2002).
   PubMed Web of Science ®Google Scholar
• Francis M, Russel RG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165, 1264–1266 (1969).
   PubMed Web of Science ®Google Scholar
• Russell RG, Rogers MJ, Frith JC et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J. Bone Miner. Res. 14(Suppl. 2), 53–65 (1999).
   PubMed Web of Science ®Google Scholar
• Rogers MJ, Frith JC, Luckman SP et al. Molecular mechanisms of action of bisphosphonates. Bone 24(5 Suppl.), 73S–79S (1999).
   PubMed Web of Science ®Google Scholar
• Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13, 581–589 (1998).
   PubMed Web of Science ®Google Scholar
• Coxon FP, Helfrich MH, Van’t Hof R et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J. Bone Miner. Res. 15, 1467–14676 (2000).
   PubMed Web of Science ®Google Scholar
• Frith JC, Monkkonen J, Auriola S et al. The molecular mechanism of action of the antiresorptive and anti-inflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum. 44, 2201–2210 (2001).
   PubMed Web of Science ®Google Scholar
• Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 25, 97–106 (1999).
   PubMed Web of Science ®Google Scholar
• Green JR. Antitumor effects of bisphosphonates. Cancer 97(3 Suppl.), 840–847 (2003).
   PubMed Web of Science ®Google Scholar
• Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer 82, 1459–1468 (2000).
   PubMed Web of Science ®Google Scholar
• van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. Clin. Invest. 98, 698–705 (1996).
   PubMed Web of Science ®Google Scholar
• Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br. J. Cancer 84, 1126–1134 (2001).
   PubMed Web of Science ®Google Scholar
• Wood J, Bonjean K, Ruetz S et al. Novel anti-angiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther. 302, 1055–1061 (2002).
   PubMed Web of Science ®Google Scholar
• Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br. J. Haematol. 116, 278–290 (2002).
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 335, 1785–1791 (1996).
   PubMed Web of Science ®Google Scholar
• Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol. 11, 59–65 (1993).
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J. 7, 377–387 (2001).
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94, 1458–1468 (2002).
   PubMed Web of Science ®Google Scholar
• Body JJ, Diel IJ, Lichinitser MR et al. MF 4265 Study Group. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. 14, 1399–1405 (2003).
   PubMed Web of Science ®Google Scholar
• Body JJ, Diel IJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled Phase III studies. Br. J. Cancer 90, 1133–1137 (2004).
   PubMed Web of Science ®Google Scholar
• Krempien B, Manegold C. Prophylactic treatment of skeletal metastases, tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphonate Cl2MBP. Cancer 72, 91–98 (1993).
   PubMed Web of Science ®Google Scholar
• Powles T, Paterson S, Kanis JA et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J. Clin. Oncol. 20, 3219–3224 (2002).
   PubMed Web of Science ®Google Scholar
• Diel IJ, Solomayer EF, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 339, 357–363 (1998).
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst. Rev. 1, CD003474 (2002).
   Google Scholar
• Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann. Oncol. 12, 1433–1438 (2001).
   PubMed Web of Science ®Google Scholar
• Atula S, Powles T, Paterson A, McCloskey E, Nevalainen J, Kanis J. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf. 26, 661–671 (2003).
   PubMed Web of Science ®Google Scholar
• Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J. Clin. Oncol. 17, 846–854 (1999).
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J. Clin. Oncol. 16, 2038–2044 (1998).
   PubMed Web of Science ®Google Scholar
• Diel IJ, Marschner N, Kindler M et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases. Proc. Am. Soc. Clin. Oncol. 18, 128a (1999) (Abstract 488).
   Google Scholar
• Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J. Clin. Oncol. 21, 4277–4284 (2003).
   PubMed Web of Science ®Google Scholar
• Body JJ. Dosing regimens and main adverse evects of bisphosphonates. Semin. Oncol. 28, 49–53 (2001).
   PubMed Web of Science ®Google Scholar
• Diel IJ, Solomayer EF, Bastert G. Treatment of metastatic bone disease in breast cancer: bisphosphonates. Clin. Breast Cancer 1, 43–51 (2000).
   PubMedGoogle Scholar
• Kohno N, Aogi K, Minami H et al. A randomized, double-blind, placebo-controlled Phase III trial of zoledronic acid in the prevention of skeletal complications in Japanese women with bone metastases from breast cancer. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 668).
   Google Scholar
• Rosen LS, Gordon DH, Dugan W Jr et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100, 36–43 (2004).
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98, 1735–1744 (2003).
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100, 2613–2621 (2004).
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial – the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol. 21, 3150–3157 (2003).
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R et al. Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst. 96, 879–882 (2004).
   PubMed Web of Science ®Google Scholar
• Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98, 962–969 (2003).
   PubMed Web of Science ®Google Scholar
• Ernst DS, Tannock IF, Winquist EW et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J. Clin. Oncol. 21, 3335–3342 (2003).
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Sydes MR, Mason MD et al. Mrc Pr05 Collaborators. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J. Natl Cancer Inst. 95, 1300–1311 (2003).
   PubMed Web of Science ®Google Scholar
• Mason MD. Development of bone metastases from prostate cancer: first results of the MRC PR04 trial (ISCRTN 61384873). Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 16).
   Google Scholar
• DesHarnais Castel L, Bajwa K, Markle JP, Timbie JW, Zacker C, Schulman KA. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support. Care Cancer 9, 545–551 (2001).
   PubMed Web of Science ®Google Scholar
• Galasko CS, Samuel AW, Rushton S, Lacey E. The effect of prostaglandin synthesis inhibitors and diphosphonates on tumour-mediated osteolysis. Br. J. Surg. 67, 493–496 (1980).
   PubMed Web of Science ®Google Scholar
• Hall DG, Stoica G. Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J. Bone Miner. Res. 9, 221–230 (1994).
   PubMed Web of Science ®Google Scholar
• Krempien B. Morphological findings in bone metastasis, tumorosteopathy and anti-osteolytic therapy. In: Metastatic Bone Disease: Fundamental and Clinical Aspects. Diel IJ, Kaufman M, Bastert G (Eds), Springer, Berlin, Germany, 59–85 (1994).
   Google Scholar
• Krempien B, Wingen F, Eichmann T, Muller M, Schmahl D. Protective effects of a prophylactic treatment with the bisphosphonate 3-amino-1-hydroxypropane-1,1-bisphosphonic acid on the development of tumor osteopathies in the rat: experimental studies with the Walker carcinosarcoma 256. Oncology 45, 41–46 (1988).
   PubMed Web of Science ®Google Scholar
• Colleoni M, O’Neill A, Goldhirsch A et al. Identifying breast cancer patients at high risk for bone metastases. J. Clin. Oncol. 18, 3925–3935 (2000).
   PubMed Web of Science ®Google Scholar
• Braun S, Cevatli BS, Assemi C et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J. Clin. Oncol. 19, 1468–1475 (2001).
   PubMed Web of Science ®Google Scholar
• Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel antitumour activity. Br. J. Haematol. 98, 665–672 (1997).
   PubMed Web of Science ®Google Scholar
• Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 58, 5294–5297 (1998).
   PubMed Web of Science ®Google Scholar
• Boissier S, Magnetto S, Frappart L et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57, 3890–3894 (1997).
   PubMed Web of Science ®Google Scholar
• Boissier S, Ferreras M, Peyruchaud O et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60, 2949–2954 (2000).
   PubMed Web of Science ®Google Scholar
• Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 61, 2602–2608 (2001).
   PubMed Web of Science ®Google Scholar
• Fournier P, Boissier S, Filleur S et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62, 6538–6544 (2002).
   PubMed Web of Science ®Google Scholar
• Algur E, Macklis RM, Hafeli UO. Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. Int. J. Radiat. Oncol. Biol. Phys. 61, 535–542 (2005).
   PubMed Web of Science ®Google Scholar
• Krempien R, Huber PE, Harms W, Treiber M, Wannenmacher M, Krempien B. Combination of early bisphosphonate administration and irradiation leads to improved remineralization and restabilization of osteolytic bone metastases in an animal tumor model. Cancer 98, 1318–1324 (2003).
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Ohlmann CH. Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease. Expert Rev. Anticancer Ther. 4, 991–1005 (2004).
   PubMedGoogle Scholar
• Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral Maxillofac. Surg. 61, 1115–1117 (2003).
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62, 527–534 (2004).
   PubMed Web of Science ®Google Scholar
• Hillner BE. Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease. Semin. Oncol. 28, 64–68 (2001).
   PubMed Web of Science ®Google Scholar
• Clamp A, Danson S, Nguyen H, Cole D, Clemons M. Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol. 5, 607–616 (2004).
   PubMed Web of Science ®Google Scholar
• Coleman RE. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 94, 2521–2533 (2002).
   PubMed Web of Science ®Google Scholar
• Fohr B, Dunstan CR, Seibel MJ. Clinical review 165. Markers of bone remodeling in metastatic bone disease. J. Clin. Endocrinol. Metab. 88, 5059–5075 (2003).
   PubMed Web of Science ®Google Scholar
• Demers LM. Bone markers in the management of patients with skeletal metastases. Cancer 97, 874–879 (2003).
   PubMed Web of Science ®Google Scholar
• Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE. Bone resorption predicts for skeletal complications in metastatic bone disease. Br. J. Cancer 89, 2031–2037 (2003).
   PubMed Web of Science ®Google Scholar
• Brown J, Cook R, Coleman R et al. The role of bone turnover markers in predicting clinical events in metastatic bone disease. Proc. Am. Soc. Clin. Oncol. 21 (2003) (Abstract 2969).
   Google Scholar
• Lipton A, Demers L, Curley E et al. Markers of bone resorption in patients treated with pamidronate. Eur. J. Cancer 34, 2021–2026 (1998).
   PubMed Web of Science ®Google Scholar
• Vinholes JJ, Purohit OP, Abbey ME, Eastell R, Coleman RE. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann. Oncol. 8, 1243–1250 (1997).
   PubMed Web of Science ®Google Scholar
• Costa L, Demers LM, Gouveia-Oliveira A et al. Prospective evaluation of the peptide-bound collagen Type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J. Clin. Oncol. 20, 850–856 (2002).
   PubMed Web of Science ®Google Scholar
• Capeller B, Caffier H, Sutterlin MW, Dietl J. Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Anticancer Res. 23(2A), 1011–1015 (2003).
   PubMed Web of Science ®Google Scholar
• Bellahcene A, Merville MP, Castronovo V. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res. 54, 2823–2826 (1994).
   PubMed Web of Science ®Google Scholar
• Withold W, Armbruster FP, Karmatschek M, Reinauer H. Bone sialoprotein in serum of patients with malignant bone diseases. Clin. Chem. 43, 85–91 (1997).
   PubMed Web of Science ®Google Scholar
• Woitge HW, Pecherstorfer M, Horn E et al. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br. J. Cancer 84, 344–351 (2001).
   PubMed Web of Science ®Google Scholar
• Koga H, Naito S, Koto S et al. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of Type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate 39, 1–7 (1999).
   PubMed Web of Science ®Google Scholar
• Noguchi M, Yahara J, Noda S. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 61, 993–998 (2003).
   PubMed Web of Science ®Google Scholar
• McKiernan JM, Delea TE, Liss M et al. Impact of skeletal complications on total medical care costs in prostate cancer patients with bone metastases. J. Clin. Oncol. 14S, 6057 (2004).
   Google Scholar
• Delea TE, McKiernan JM, Liss M et al. Impact of skeletal complications on total medical care costs in lung cancer patients with bone metastases. J. Clin. Oncol. 14S, 60–64 (2004).
   Google Scholar
• Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J. Clin. Oncol. 18, 1570–1593 (2000).
   PubMed Web of Science ®Google Scholar
• Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J. Clin. Oncol. 15, 1341–1347 (1997).
   PubMed Web of Science ®Google Scholar
• Mundy GR. The evolving role of bisphosphonates: cancer treatment-induced bone loss. Oncology (Huntingt.) 18, 9–10 (2004).
   PubMedGoogle Scholar
• Hultborn R, Gundersen S, Ryden S et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res. 19, 3383–3392 (1999).
   PubMed Web of Science ®Google Scholar
• Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J. Intern. Med. 246(1), 67–74 (1999).
   PubMed Web of Science ®Google Scholar
• Tubiana-Hulin M, Beuzeboc P, Mauriac L et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull. Cancer 88, 701–707 (2001).
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst. Rev. 1, CD003474 (2002).
   Google Scholar